CLINUVEL Pharmaceuticals is an Australian specialty biopharmaceutical company commercializing SCENESSE (afamelanotide) for phototoxicity in erythropoietic protoporphyria.
CLINUVEL Pharmaceuticals, headquartered in Melbourne, Australia, is a listed specialty biopharmaceutical group working across pharmaceuticals and photomedicine. The company holds the rights to afamelanotide, a melanocortin-1 receptor agonist it markets under the SCENESSE brand as a subcutaneous implant that increases pain-free light exposure in adults with phototoxic reactions from erythropoietic protoporphyria.
SCENESSE received European approval in 2014 and U.S. FDA approval in 2019, making it the first approved therapy for the light sensitivity caused by protoporphyria, and CLINUVEL distributes it through subsidiaries including a U.S. arm.
SCENESSE (afamelanotide) is CLINUVEL's approved subcutaneous melanocortin-1 receptor agonist implant that increases pain-free light exposure in adults with erythropoietic protoporphyria.
